Advancements in Alzheimer's Research: New Tools and Therapeutics

Thermo Fisher Scientific Inc. has introduced the Olink® Target 48 Neurodegeneration panel, a targeted proteomics immunoassay designed to enhance research in neurodegenerative diseases such as Alzheimer’s, multiple sclerosis, and Parkinson’s. This panel allows for the simultaneous measurement of 41 critical proteins relevant to neurodegeneration, utilizing only 1µL of plasma sample. Yan Zhang, President of the Proteomic Sciences business at Thermo Fisher, emphasized the panel's role in providing absolute quantification of biomarkers, which is essential for monitoring disease progression and therapeutic responses. The panel is part of a broader suite of tools aimed at advancing precision medicine and is compatible with Thermo Fisher’s global network of Olink-equipped laboratories, facilitating reproducibility across multi-center trials.

Technology NetworksPsypostUSC researchers win $8M NIH grant to pursue Alzheimer’s drug

Researchers at the University of Southern California (USC) have secured an $8 million grant from the National Institutes of Health to develop a new drug targeting the enzyme calcium-dependent phospholipase A2 (cPLA2), which is linked to inflammation in Alzheimer’s disease. Led by Hussein Yassine, the team aims to understand why certain carriers of the APOE4 gene develop dementia while others remain cognitively healthy. The research focuses on blocking cPLA2 to mitigate inflammation and enhance the protective effects of omega-3 fatty acids in the brain. This collaborative effort combines expertise from various USC schools, utilizing artificial intelligence to identify potential drug candidates.

USC researchers win $8M NIH grant to pursue Alzheimer’s drugPsypostRethinking Alzheimer’s: Why this common gene variant is bad for your brainTechnology Networks

A recent study has indicated that sodium benzoate, a compound derived from cinnamon, may reduce amyloid-beta levels in the blood of patients with mild Alzheimer’s disease. Conducted as a secondary analysis of a previous clinical trial, the research found that higher initial levels of amyloid-beta 1–42 correlated with greater cognitive improvements following treatment. The study suggests that sodium benzoate could offer a safer and more accessible therapeutic option compared to existing intravenous treatments, which often come with significant side effects and logistical challenges.

PsypostUSC researchers win $8M NIH grant to pursue Alzheimer’s drugTechnology Networks

The APOE4 gene variant significantly increases the risk of developing Alzheimer’s disease, with carriers showing symptoms earlier than those with the more common APOE3 variant. Research indicates that while about 25% of individuals of European descent carry APOE4, its prevalence among Alzheimer’s patients is much higher. Recent findings suggest that the presence of APOE4 may not only predispose individuals to Alzheimer’s but could also be toxic, as evidenced by a study where two elderly individuals with defective APOE4 copies exhibited no signs of cognitive decline.

Rethinking Alzheimer’s: Why this common gene variant is bad for your brainPsypost

The advancements in neurodegenerative research tools and potential therapies highlight a multifaceted approach to tackling Alzheimer’s disease. The Olink® Target 48 Neurodegeneration panel, USC’s drug development efforts, and the promising results from sodium benzoate studies represent significant strides in understanding and treating this complex condition. As researchers continue to explore the implications of genetic factors like APOE4, the hope is to develop targeted therapies that can effectively address the underlying mechanisms of Alzheimer’s disease.

Technology Networks

• “The Target 48 Neurodegeneration panel is a critical tool that enables the detection and quantification of key and emerging neurodegenerative disease biomarkers from plasma and cerebrospinal fluid samples. By generating quantitative data, it ensures reproducible results across and within longitudinal studies, moving a step forward towards clinical utilization.” — Charlotte Teunissen, Professor in Neurochemistry, Amsterdam University Medical Center

Technology Networks

• “Using support from NIH, we are translating these discoveries into a drug that can get into the clinic,” — Stan Louie, Pharmacologist, USC Alfred E. Mann School of Pharmacy

USC researchers win $8M NIH grant to pursue Alzheimer’s drug

• “Sodium benzoate treatment decreased amyloid beta peptides and improved cognitive function among patients with Alzheimer’s disease: secondary analysis of a randomized clinical trial,” — Chieh-Hsin Lin, Researcher, Chang Gung University

Psypost

While the studies on sodium benzoate show promise, limitations such as sample size and duration raise questions about the long-term efficacy and applicability across diverse populations. Additionally, the relationship between blood and brain amyloid-beta levels remains to be fully elucidated, necessitating further research to confirm these findings.

Psypost